Skip to main content

Lonza Group

Lonza Group AG is a Swiss multinational biopharmaceutical contract development and manufacturing organization (CDMO) supplying life sciences industries globally. The company conducts its business through four reportable business segments: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Its commercial technical portfolio encompasses contract development of monoclonal antibodies, cell therapy production, small-molecule drug synthesis, and capsule delivery systems. Principal revenue drivers consist of long-term contract manufacturing agreements, clinical trial batch manufacturing, process development fees, and specialty capsule sales to pharmaceutical brands. Lonza Group serves broad global health end markets including major pharmaceutical corporations, emerging biotechnology firms, consumer health brands, and clinical research institutions. The enterprise holds a dominant global market position as a premier contract development and manufacturing organization for complex biologic and cell-based drugs. Headquartered in Basel, Switzerland, the company's common stock is primary listed on the SIX Swiss Exchange under the ticker symbol LONN and holds a secondary listing on the SGX.

82 of the funds FundTelligence covers report a position in Lonza Group.

Sector
Health Care
Country
Switzerland
Funds holding it
82

Funds holding Lonza Group

Showing the 8 largest of 82 funds holding it.

Loading...